Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Chemomab Therapeutics Ltd. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +1 vs. Q4 2021
- Shares held
- 3.31M
- +19.5K (+0.6%) vs. Q4 2021
- Total value
- $15.9M
- −$6.81M (−30.0%) vs. Q4 2021
- New holders
- 6
- 4 more added
- Sold out
- 5
- 3 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 260 | $1.00K | 0.00% | +260 | New |
| ARK Investment Management LLCSuperinvestorARK Invest | 792 | $4.00K | 0.00% | −266,500−99.7% | Reduced |
| UBS Group AG | 885 | $4.00K | 0.00% | −960−52.0% | Reduced |
| JPMorgan Chase & Co | 753 | $4.00K | 0.00% | +753 | New |
| Newbridge Financial Services Group, Inc. | 1,100 | $5.00K | 0.00% | +1,100 | New |
| Advisor Group Holdings, Inc. | 7,144 | $34.0K | 0.00% | +2,754+62.7% | Added |
| Envestnet Asset Management Inc | 10,807 | $52.0K | 0.00% | +10,807 | New |
| Geode Capital Management, LLC | 11,737 | $56.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 27,960 | $134.0K | 0.00% | +27,960 | New |
| Meitav Dash Investments Ltd | 35,024 | $167.0K | 0.00% | −2,543−6.8% | Reduced |
| State Street Corp | 35,406 | $171.0K | 0.00% | +2,717+8.3% | Added |
| Boothbay Fund Management, LLC | 41,298 | $198.0K | 0.01% | +12,645+44.1% | Added |
| Ikarian Capital, LLC | 268,104 | $1.29M | 0.39% | +2,840+1.1% | Added |
| Cormorant Asset Management, LP | 288,168 | $1.38M | 0.11% | +288,168 | New |
| OrbiMed Advisors LLC | 2,578,174 | $12.4M | 0.20% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −22,441−100.0% | Sold out |
| Apollon Wealth Management, LLC | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −11,643−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −11,277−100.0% | Sold out |
| Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 0 | $0 | 0.00% | −3,097−100.0% | Sold out |